Shan Li

Title: Innovations by Inventor Shan Li

Introduction

Shan Li is a prominent inventor based in Emeryville, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of constructs targeting specific antigens for therapeutic applications. With a total of 2 patents, his work is paving the way for advancements in cancer treatment.

Latest Patents

Shan Li's latest patents include constructs targeting prostate-specific membrane antigen (PSMA) and constructs targeting CD22. The first patent provides constructs comprising an antibody moiety that specifically binds to PSMA, which is expressed on the surface of certain cells. This innovation includes methods for making and using these constructs, potentially leading to new therapeutic options for prostate cancer. The second patent describes antibodies, particularly single chain variable fragment (scFv) antibodies, that bind to the extracellular domain of CD22. This work is crucial for the therapeutic treatment of diseases characterized by CD22 expression, such as B-cell lymphomas and leukemias.

Career Highlights

Shan Li is currently associated with Eureka Therapeutics, Inc., where he continues to innovate in the field of antibody-based therapies. His expertise and research are instrumental in developing new treatments that target specific cancer cells, enhancing the efficacy of therapeutic interventions.

Collaborations

Shan Li collaborates with notable colleagues, including Hong Liu and Hongruo Yun. Their combined efforts contribute to the advancement of research and development in the biotechnology sector.

Conclusion

In summary, Shan Li is a dedicated inventor whose work in developing targeted constructs has the potential to revolutionize cancer treatment. His contributions to the field are significant and continue to inspire further research and innovation.